FDA approval for VNS Therapy will help people with epilepsy

NewsGuard 100/100 Score

The U.S. Food and Drug Administration's recent approval of Vagus Nerve Stimulation Therapy for treatment of chronic depression provides a novel single-treatment option for two major symptoms suffered by people with epilepsy.

There are 2.7 million Americans with epilepsy, and an estimated 36 percent of them suffer from clinical depression. VNS Therapy, a form of treatment in use to control seizures, now offers the potential of making life better for people with epilepsy by mitigating both the seizures and the accompanying mood disorder.

Depression is one of the most under-recognized and under-treated conditions in people with epilepsy. According to a recent study out of New York University, depression has a significantly greater negative impact on quality of life than the seizures themselves. Vagus Nerve Stimulation entails having a small electrical device implanted in the patient's chest and connected to the vagus nerve at the side of the neck. Manufactured by Cyberonics, the device delivers small bursts of electricity at various intervals to prevent a seizure from happening. It has become a common method of treatment for epilepsy since its approval by the FDA in 1997.

"We are extremely pleased with the FDA's approval of VNS Therapy as a long-term adjunctive treatment in chronic depression. Depression affects more than a third of all individuals with epilepsy," said Eric Hargis, president and CEO of the national Epilepsy Foundation. "Yet, it is greatly under- diagnosed in people with seizure disorders. The FDA decision offers a significant new treatment option for patients and families affected by these co-existing conditions."

In addition to the depression associated with epilepsy itself, the mood disorder is correlated with being either a young female adult, having lower income, lower rates of employment, more disability, more social concerns and more side effects due to antiepileptic medication. The Epilepsy Foundation has several initiatives in place meant to address and combat this psychological impact of epilepsy.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
More than 3 billion people worldwide lived with a neurological condition in 2021, new study reports